Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Extracorporeal perfusion apparatus

A technology of in vitro perfusion and equipment, which can be used in extracellular fluid diseases, alkali metal oxides/hydroxides, inorganic chemistry, etc., and can solve the problem of high mortality of patients

Active Publication Date: 2015-04-29
FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
View PDF22 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0035] Although the mortality rate of patients with endotoxemia-induced conditions, especially sepsis, can be reduced by the above-mentioned clinical application of polymyxin-based adsorbent materials, severe sepsis and sepsis despite maximal treatment The mortality rate of patients with toxic shock is still very high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Extracorporeal perfusion apparatus
  • Extracorporeal perfusion apparatus
  • Extracorporeal perfusion apparatus

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0127] 1. Example 1: Differently with polymyxin B (PMB) coated carrier (average particle size: 120 microns, average pore size: 15-20 nm) PMB in plasma and separated plasma (using Albuflow filter ) desorption in

[0128] 1.1PMB coating

[0129] Support: Amberchrom CG161c (polystyrene-divinylbenzene copolymer, The Dow Chemical Company), with an average particle size of 120 micrometers and an average pore size of 15 nanometers; accessible surface is 900 square meters per gram of polymer (dry) rice. The dry weight per milliliter of wet carrier was 18% (weight / volume).

[0130] Polymyxin B (PMB): Polymyxin B sulfate (Sigma Aldrich)

[0131] The PMB solution (10 mg / ml in distilled water) was autoclaved at 121° C. for 30 minutes, and the carrier was then coated with PMB in a 15 ml Greiner tube as follows (Table 1.1): 3 ml carrier with 7.5 ml PMB solution

[0132] Table 1.1

[0133]

[0134] The coating was performed overnight on a tumble mixer at room temperature. The car...

example 2

[0145] 2. Example 2: Endotoxin batches in serum with different PMB-coated carriers

[0146] 2.1 Test structure

[0147] The conditioned carrier (Amberchrom CG161c: Ethylvinylbenzene-divinylbenzene copolymer (The Dow Chemical Company), with an average particle size of 120 μm and an average pore size of 15 nm) was treated with different amounts of polymyxin B (PMB) as coating: 0, 5, 10, 15 and 25 mg per gram of wet carrier. These were tested for inactivation of LPS in serum in an endotoxin batch test in triplicate.

[0148] 2.2 Execution of the test

[0149] PMB coating:

[0150] Samples of the vehicle were produced at different PMB concentrations (5 mg, 10 mg, 15 mg and 25 mg per gram of wet vehicle) (see protocol in Example 1 above). PMB solution (10 mg / ml in distilled water) with the carrier in a 50% suspension was autoclaved at 121°C for 30 minutes, and the carrier was coated with PMB in a 15 ml Glenner tube as follows (Table 2.2) :

[0151] Table 2.2:

[0152] ...

example 3

[0161] 3. Example 3: Inactivation of endotoxin (LPS) according to the concentration of polymyxin based on endotoxins from Escherichia coli and Pseudomonas aeruginosa.

[0162] 3.1. Goals

[0163] The objective of this test is to determine the inactivation of endotoxin in plasma as a function of polymyxin B (PMB) concentration (batch test I). Furthermore, it was investigated to what extent this endotoxin inactivation leads to inhibition of cytokine diffusion (batch test II).

[0164] 3.2. Blood donors

[0165] Nine blood sample tubes (9 ml each) spiked with 5 IU of heparin were taken from the donor. Plasma was separated by centrifuge and cell pellets were incubated on a roller mixer. Endotoxin (LPS) spiked into plasma used for batch test I:

[0166] 3.3. Incorporation of LPS, polymyxin B solution and batch test I

[0167] LPS: Pseudomonas aeruginosa (L-7018Sigma Lot: 128K4115, -70°C, 100 μl 10 -3 g / mL (1 mg / mL))

[0168] LPS: Escherichia coli (L-4130Sigma Lot: 110M...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
porosityaaaaaaaaaa
porosityaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

Sorption agent for treating diseases and conditions associated with an increased concentration of at least one inflammation mediator, preferably cytokine, comprises a porous sorption matrix with a neutral, hydrophobic surface, an average pore size of 11-20 nm and an average particle size of 75-150 mu m. Independent claims are also included for: (1) a sorption device comprising at least one sorption agent; and (2) an extracorporeal perfusion device comprising at least one sorption agent. ACTIVITY : Antibacterial; Immunosuppressive; Hepatotropic; Antiinflammatory; Virucide; Antiarthritic; Antirheumatic; Gastrointestinal-Gen; Antipsoriatic. Test details are described but no results given. MECHANISM OF ACTION : None given.

Description

technical field [0001] The present invention relates to an extracorporeal perfusion device comprising an extracorporeal blood flow path for delivering blood, a filtrate flow path for delivering plasma, and a controller, wherein the filtrate flow path is connected to the extracorporeal blood flow path with a filter, Wherein the filter has a sieving coefficient of 5% for substances having a molar mass of 340,000 g / mol (relative molecular mass of 340 kDa), and wherein a consumable substance is arranged in the filtrate flow path, the consumable substance comprising a first carrier, which Has a neutral, hydrophobic surface. Background technique [0002] Sepsis and associated complications cause considerable morbidity and mortality in humans. In most cases, sepsis is attributable to infection by Gram-negative bacteria, when high endotoxin concentrations reach the body and have systemic effects. [0003] Endotoxins are lipopolysaccharides (LPS) in the cell walls of Gram-negative ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): B01J20/28B01J20/32B01J20/26A61K31/745A61M1/36
CPCA61M1/3486A61K31/745A61K38/12A61M1/3472A61M1/3679B01J20/261B01J20/264B01J20/28004B01J20/28016B01J20/28019B01J20/28061B01J20/28064B01J20/28066B01J20/28083B01J20/28085B01J20/321B01J20/3214B01J20/3246B01J20/3274A61M2202/0413A61M2205/75A61M2202/049A61M2202/0456A61M2205/3303A61P1/16A61P29/00A61P31/04A61P7/00
Inventor 迪特尔·法尔肯哈根简·哈特曼史蒂芬·哈姆
Owner FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com